Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.
about
Drug Development in Alzheimer's Disease: The Contribution of PET and SPECTAn Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and DementiaNicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersThe Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.Cognitive impairment in schizophrenia: the great unmet need.Alzheimer's disease: current and future therapy.Interactions of Tryptophan and Its Catabolites With Melatonin and the Alpha 7 Nicotinic Receptor in Central Nervous System and Psychiatric Disorders: Role of the Aryl Hydrocarbon Receptor and Direct Mitochondria Regulation.Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials.Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model.Allosteric Modulators of the M4 Muscarinic Acetylcholine Receptor.A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia.
P2860
Q26749755-5E33AA5B-F67F-4C66-9231-0688C99759CAQ28067460-77E27431-80B7-4865-9DAF-7813AFF68054Q30372351-0B89B932-1428-4BD1-B17B-470138E65A5DQ36088364-95E03618-FEDF-48EF-95D9-37F0BDB80E2CQ37258840-51A99170-F965-4AAF-986E-B940B9FBDDF9Q37346136-40EB2570-EEA2-4ECF-A3CD-667E4DB1B088Q38560778-5D9429FF-46D0-4D31-A752-567FCDDAE7FCQ38673548-4AB5F1FA-A98E-4FAE-B1A7-86A4F9A340D8Q39061965-D7B97569-6E76-4A7A-81D9-64F399F024BDQ39281814-74B7C086-1B07-40EB-A718-D1850A0AE112Q46315298-5015CEE4-6F4E-4A56-80C9-9F0C83E546E0Q47127039-043FF065-A4BE-4D8B-A1E4-995F2826A14AQ47158626-E5328E46-3F60-4996-B3D5-C2EF5046C9C4Q48113629-CFEBF4E8-AD1A-40E9-A3F1-0F2EE6130A0CQ49838298-ED707DDD-A79E-4ECF-A968-4EFC175B84D4Q54943548-C4D51E74-89D4-46D8-838B-0BBE9B062F50
P2860
Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Safety and clinical effects of ...... esterase inhibitor medication.
@en
type
label
Safety and clinical effects of ...... esterase inhibitor medication.
@en
prefLabel
Safety and clinical effects of ...... esterase inhibitor medication.
@en
P2093
P2860
P1476
Safety and clinical effects of ...... esterase inhibitor medication.
@en
P2093
Ahmad Shobassy
George T Grossberg
William James Deardorff
P2860
P356
10.1586/14737175.2015.995639
P577
2014-12-15T00:00:00Z